HILLIARD, Ohio--(BUSINESS WIRE)--Advanced Drainage Systems, Inc. (ADS) (NYSE: WMS), a leading provider of innovative water management solutions, today released the Nyloplast 12-inch universal inline drain solution designed for contractors seeking a durabl
VICTORIA, British Columbia--(BUSINESS WIRE)--$IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody discovery and development, today announced fina
LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita”), a growth-oriented, innovation-driven Canadian commercial dermatology company, is pleased to announce that it has signed an exclusive commercializati
Primary efficacy endpoint statistically significant with 34% placebo-adjusted reduction in 24-hour cough frequency observed at 50 mg and 200 mg BID doses (p ≤ 0.005) BLU-5937 was well-tolerated with a low rate of taste-related adverse events (≤6.5%)
OTTAWA, Ontario--(BUSINESS WIRE)--#NetZero--The Net Zero Company Ltd. (“NZC”), a specialized emissions reduction and offsetting company, has received a strategic investment from Altius Minerals Corporation (Altius) (TSX:ALS) (OTCQX: ATUSF), a streamin
Updated data from the pivotal cohort of HGB-206 reinforce that optimized manufacturing and treatment processes are associated with improved biologic and clinical outcomes, including stable production of gene therapy-derived anti-sickling hemoglobin and c
Not for Distribution to U.S. News Wire Services or Dissemination in the United States SASKATOON, Saskatchewan & LONDON--(BUSINESS WIRE)--Gensource Potash Corporation (“Gensource” or the “Company”) (TSXV: GSP, AIM: GSP) today announced that it has
CHICAGO--(BUSINESS WIRE)--Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced today the closing of the Company
TORONTO--(BUSINESS WIRE)--#CBIV--Cross-Border Impact Ventures (CBIV) today announced the launch of the firm and its Women’s and Children’s Health Technology Fund, which will invest in health technology companies that address the health needs of women,
LAVAL, Quebec--(BUSINESS WIRE)--#AcuteKidneyInjury--Altasciences is pleased to have been chosen by XORTX Therapeutics, Inc. to conduct a pharmacokinetic bridging study in support of the XRx-008 program for autosomal dominant polycystic kidney disease (ADP
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.